These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 24647611)

  • 21. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
    Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
    J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
    Pierre F; Chua PC; O'Brien SE; Siddiqui-Jain A; Bourbon P; Haddach M; Michaux J; Nagasawa J; Schwaebe MK; Stefan E; Vialettes A; Whitten JP; Chen TK; Darjania L; Stansfield R; Bliesath J; Drygin D; Ho C; Omori M; Proffitt C; Streiner N; Rice WG; Ryckman DM; Anderes K
    Mol Cell Biochem; 2011 Oct; 356(1-2):37-43. PubMed ID: 21755459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking.
    Di-wu L; Li LL; Wang WJ; Xie HZ; Yang J; Zhang CH; Huang Q; Zhong L; Feng S; Yang SY
    J Mol Graph Model; 2012 Jun; 36():42-7. PubMed ID: 22516037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural basis for low-affinity binding of non-R2 carboxylate-substituted tricyclic quinoline analogs to CK2α: comparative molecular dynamics simulation studies.
    Zhou Y; Li X; Zhang N; Zhong R
    Chem Biol Drug Des; 2015 Feb; 85(2):189-200. PubMed ID: 24903887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ROCK2-Specific Inhibitor KD025 Suppresses Adipocyte Differentiation by Inhibiting Casein Kinase 2.
    Tran NNQ; Chun KH
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3D-QSAR-aided design of potent c-Met inhibitors using molecular dynamics simulation and binding free energy calculation.
    Balasubramanian PK; Balupuri A; Bhujbal SP; Cho SJ
    J Biomol Struct Dyn; 2019 May; 37(8):2165-2178. PubMed ID: 30044205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insight into the selective mechanism of phosphoinositide 3-kinase γ with benzothiazole and thiazolopiperidine γ-specific inhibitors by in silico approaches.
    Zhu J; Li K; Xu L; Jin J
    Chem Biol Drug Des; 2019 May; 93(5):818-831. PubMed ID: 30582283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rational Design of Coumarin Derivatives as CK2 Inhibitors by Improving the Interaction with the Hinge Region.
    Zhang N; Chen WJ; Zhou Y; Zhao H; Zhong RG
    Mol Inform; 2016 Jan; 35(1):15-8. PubMed ID: 27491649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Theoretical Studies on the Selectivity Mechanisms of Glycogen Synthase Kinase 3β (GSK3β) with Pyrazine ATP-competitive Inhibitors by 3DQSAR, Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculations.
    Zhu J; Wu Y; Xu L; Jin J
    Curr Comput Aided Drug Des; 2020; 16(1):17-30. PubMed ID: 31284868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors.
    Ferrari AM; Degliesposti G; Sgobba M; Rastelli G
    Bioorg Med Chem; 2007 Dec; 15(24):7865-77. PubMed ID: 17870536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding microscopic binding of macrophage migration inhibitory factor with phenolic hydrazones by molecular docking, molecular dynamics simulations and free energy calculations.
    Xu L; Li Y; Li L; Zhou S; Hou T
    Mol Biosyst; 2012 Sep; 8(9):2260-73. PubMed ID: 22739754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of dual kinase inhibitors of CK2 and GSK3β: combined qualitative and quantitative pharmacophore modeling approach.
    Pardhi T; Vasu K
    J Biomol Struct Dyn; 2018 Jan; 36(1):177-194. PubMed ID: 27960601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-4-ones as a new class of CK2 inhibitors.
    Protopopov MV; Ostrynska OV; Starosyla SA; Vodolazhenko MA; Sirko SM; Gorobets NY; Bdzhola V; Desenko SM; Yarmoluk SM
    Mol Divers; 2018 Nov; 22(4):991-998. PubMed ID: 29845490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design of 2-amino-6-methyl-pyrimidine benzoic acids as ATP competitive casein kinase-2 (CK2) inhibitors using structure- and fragment-based design, docking and molecular dynamic simulation studies.
    Patel S; Patel S; Tulsian K; Kumar P; Vyas VK; Ghate M
    SAR QSAR Environ Res; 2023 Mar; 34(3):211-230. PubMed ID: 37051759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Features and potentials of ATP-site directed CK2 inhibitors.
    Sarno S; Salvi M; Battistutta R; Zanotti G; Pinna LA
    Biochim Biophys Acta; 2005 Dec; 1754(1-2):263-70. PubMed ID: 16198160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.
    Yang Y; Shen Y; Liu H; Yao X
    J Chem Inf Model; 2011 Dec; 51(12):3235-46. PubMed ID: 22097958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance.
    D'Amore C; Borgo C; Sarno S; Salvi M
    Cell Oncol (Dordr); 2020 Dec; 43(6):1003-1016. PubMed ID: 33052585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multisite-directed inhibitors of protein kinase CK2: new challenges.
    Świder R; Masłyk M; Martín-Santamaría S; Ramos A; de Pascual-Teresa B
    Mol Cell Biochem; 2011 Oct; 356(1-2):117-9. PubMed ID: 21750979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site.
    Bestgen B; Krimm I; Kufareva I; Kamal AAM; Seetoh WG; Abell C; Hartmann RW; Abagyan R; Cochet C; Le Borgne M; Engel M; Lomberget T
    J Med Chem; 2019 Feb; 62(4):1803-1816. PubMed ID: 30689953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular modeling study of CP-690550 derivatives as JAK3 kinase inhibitors through combined 3D-QSAR, molecular docking, and dynamics simulation techniques.
    Wang JL; Cheng LP; Wang TC; Deng W; Wu FH
    J Mol Graph Model; 2017 Mar; 72():178-186. PubMed ID: 28107751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.